Page last updated: 2024-12-05

2-vanillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Vanillin, also known as isovanillin, is a naturally occurring organic compound with the molecular formula C8H8O3. It is a white crystalline solid with a strong vanilla-like aroma. 2-Vanillin is a positional isomer of vanillin, where the methoxy group is located at the 2-position instead of the 3-position. It is a valuable intermediate in the synthesis of various pharmaceuticals, flavors, and fragrances. Its synthesis involves the oxidation of eugenol, a naturally occurring compound found in cloves. 2-Vanillin is studied for its potential applications in medicine, as an antioxidant, and as a precursor for the production of other valuable compounds. It is a promising candidate for the development of novel drugs due to its reported biological activity and its ability to modulate various signaling pathways in the human body. 2-Vanillin is also investigated for its potential use in the food industry, where it can serve as a natural flavoring agent and as a possible replacement for synthetic vanilla extracts. The unique structure of 2-vanillin, with its methoxy group at the 2-position, is responsible for its distinct aroma and its biological activity. Researchers are actively studying the potential benefits of 2-vanillin in various fields, contributing to a growing understanding of this interesting compound.'

ortho-vanillin : A member of the class of benzaldehydes that is salicylaldehyde substituted by a methoxy group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8991
CHEMBL ID13859
CHEBI ID78339
SCHEMBL ID16004
MeSH IDM0168868

Synonyms (66)

Synonym
3-methoxysalicylaldehyde
2-hydroxy-3-methoxybenzaldehyde
wln: vhr bq co1
oxy-2 methoxy-3 benzaldehyde
nsc2150
6-formylguaiacol
o-vanilline
nsc-2150
148-53-8
o-vanillin
benzaldehyde, 2-hydroxy-3-methoxy-
m-anisaldehyde, 2-hydroxy-
3-methoxy-2-hydroxybenzaldehyde
6-formyl-2-methoxyphenol
2-hydroxy-m-anisaldehyde
2-hydroxy-3-(methyloxy)benzaldehyde
nsc 2150
ai3-00076
brn 0471913
oxy-2 methoxy-3 benzaldehyde [french]
orthovanilline
einecs 205-715-3
2-hydroxy,3-methoxy-benzaldehyde (o-vanillin)
inchi=1/c8h8o3/c1-11-7-4-2-3-6(5-9)8(7)10/h2-5,10h,1h
o-vanillin, 99%
2-vanillin
STK397284
AC-11135
chebi:78339 ,
CHEMBL13859
H0262
AKOS000119724
A808779
2-hydroxy-3-methoxy-benzaldehyde
BBL009824
008lr748fi ,
ccris 8811
unii-008lr748fi
FT-0616020
0-vanillin
2-hydroxy-3 methoxybenzaldehyde
3-methoxy-2-hydroxy-benzaldehyde
o-vaniline
2-hydroxy-3-methoxy benzaldehyde
us8614253, .3-63
bdbm111024
us8614253, .3-55
SCHEMBL16004
ortho-vanillin
ortho vanillin
Q-201522
NS-00006
mfcd00003322
2-hydroxyl-3-methoxybenzaldehyde
hydroxy-3-methoxybenzaldehyde, 2-
DTXSID5022011
CS-W008876
F2190-0634
P20004
Q309747
AMY18059
EN300-18431
bis(i-propylcyclopentadienyl)titaniumdichloride
2-hydroxy-3-methoxybenzaldehyde o-vanillin
HY-Y1832
Z57921503

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Furthermore, bioavailability and efficacy were verified ex vivo in the physiological environment of degenerating intact human discs where a single dose improved disc matrix homeostasis."( Senotherapeutic drugs for human intervertebral disc degeneration and low back pain.
Bisson, DG; Cherif, H; Haglund, L; Mannarino, M; Ouellet, JA; Rabau, O, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimutagenAn agent that reduces or interferes with the mutagenic actions or effects of a substance.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzaldehydesAny arenecarbaldehyde that consists of a formyl substituted benzene ring and its substituted derivatives thereof.
guaiacolsAny phenol carrying an additional methoxy substituent at the ortho-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID293934Inhibition of pieris rapae Phenoloxidase2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1291732Protective activity against Daboia russellii venom-induced defibrinogenation in iv dosed Swiss albino mouse assessed as venom level causing blood coagulation at 100 mmol administered immediately after venom injection (Rvb = 2.5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1484011Inhibition of amyloid beta (1 to 42) aggregation in Escherichia coli competent cells BL21 (DE3) at 200 uM after overnight incubation by Thioflavin-S steady-state fluorescence assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.
AID1291713Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291717Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID322956Inhibition of synthetic amyloid beta42 oligomer formation by Western blot2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1291714Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mo2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291720Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291721Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291711Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291731Protective activity against Daboia russellii venom-induced defibrinogenation in iv dosed Swiss albino mouse assessed as venom level causing blood coagulation at 100 mmol preincubated with venom for 1 hr followed by administration to mouse (Rvb = 2.5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291724Protective activity against Daboia russellii venom-induced mortality in iv dosed Swiss albino mouse administered 30 mins after venom injection relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291715Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative t2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1291722Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291726Protective activity against Naja kaouthia venom-induced mortality in iv dosed Swiss albino mouse assessed as administered 30 to 60 mins after venom injection2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291718Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291728Protective activity against Daboia russellii venom-induced defibrinogenation in iv dosed Swiss albino mouse assessed as blood coagulation at 100 mmol administered immediately after venom injection relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291719Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291729Protective activity against Daboia russellii venom-induced coagulation in goat plasma assessed as increase in plasma recalcification time at 20 mmol preincubated with venom for 1 hr followed by plasma addition2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1291710Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291725Protective activity against Daboia russellii venom-induced mortality in iv dosed Swiss albino mouse administered 60 mins after venom injection relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID1291727Protective activity against Daboia russellii venom-induced defibrinogenation in iv dosed Swiss albino mouse assessed as venom level causing blood coagulation at 100 mmol preincubated with venom for 1 hr followed by administration to mouse relative to untr2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID1291712Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1291723Protective activity against Daboia russellii venom-induced mortality in iv dosed Swiss albino mouse administered immediately after venom injection relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (16.67)18.7374
1990's5 (10.42)18.2507
2000's9 (18.75)29.6817
2010's15 (31.25)24.3611
2020's11 (22.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.99 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]